List of Excipients in Branded Drug NALOXONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Summit Biosciences Inc	NALOXONE	naloxone	43674-003	GLYCERIN
Summit Biosciences Inc	NALOXONE	naloxone	43674-003	HYDROCHLORIC ACID
Summit Biosciences Inc	NALOXONE	naloxone	43674-003	SODIUM HYDROXIDE
Summit Biosciences Inc	NALOXONE	naloxone	43674-003	TRISODIUM CITRATE DIHYDRATE

Generic Drugs Containing NALOXONE

Company	Ingredient	NDC	Excipient
HF Acquisition Co LLC DBA Health First	naloxone hci	51662-1242	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA Health First	naloxone hci	51662-1242	SODIUM CHLORIDE
HF Acquisition Co LLC DBA Health First	naloxone hci	51662-1242	WATER
Teva Pharmaceuticals USA Inc	naloxone hydrochloride	0093-2165	BENZALKONIUM CHLORIDE

What are the Most Frequently-Used Excipients in NALOXONE?

# Of NDCs	Excipient

Naloxone Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Naloxone has become a high-volume, multi-channel rescue medicine with limited differentiation from the active ingredient alone. The strongest commercial opportunities are in nasal delivery, low-cost OTC products, public-sector procurement, pediatric and veterinary formats, device usability, shelf-life, and manufacturing scale. Excipients can improve stability, spray performance, tolerability, and package compatibility, but the largest barriers are usually device engineering, regulatory evidence, supply reliability, and market access rather than novel chemistry.

What naloxone products are commercially available?

Naloxone hydrochloride is marketed in injectable, intranasal, autoinjector, and prefilled-syringe formats. The principal U.S. products are summarized below.

Product	Sponsor or manufacturer	Route	Strength	U.S. status	Commercial position
Narcan	Emergent BioSolutions	Intranasal	4 mg/0.1 mL	OTC and prescription	First major branded OTC nasal product
Generic naloxone nasal spray	Teva and other manufacturers	Intranasal	4 mg/0.1 mL	Prescription and OTC pathways	Price competition and broad access
Kloxxado	Hikma Pharmaceuticals	Intranasal	8 mg/0.1 mL	Prescription	Higher-dose product for suspected potent-opioid exposure
RiVive	Harm Reduction Therapeutics	Intranasal	3 mg/0.1 mL	OTC	Nonprofit-backed public-health product
Zimhi	Adamis Pharmaceuticals, acquired by Corium	Intramuscular	5 mg/0.5 mL	Prescription	High-dose prefilled syringe
Generic injectable naloxone	Multiple manufacturers	IV, IM, subcutaneous	Several concentrations	Prescription	Hospitals, emergency services and institutional use
Evzio	kaleo	Autoinjector	2 mg/0.4 mL	Approved; commercial availability has been limited	Device-led, premium rescue format

Narcan was approved for nonprescription use in March 2023, and FDA authorized its OTC sale in July 2023. RiVive received FDA approval for OTC use in 2023. Teva received FDA approval for an OTC naloxone nasal spray in 2024, expanding the low-cost competitive segment.[1-3]

What excipients are used in naloxone nasal sprays?

Commercial naloxone nasal sprays generally use a simple aqueous formulation. Typical inactive ingredients include sodium chloride, benzalkonium chloride, hydrochloric acid and purified water. The excipient system is designed to maintain a near-physiologic solution, control pH, preserve the product during multidose or single-use shelf life, and support reproducible nasal atomization.

Excipient or component	Primary function	Commercial relevance
Sodium chloride	Tonicity adjustment	Can reduce nasal discomfort and improve formulation compatibility
Hydrochloric acid	pH adjustment	Supports naloxone stability and target nasal tolerability
Benzalkonium chloride	Antimicrobial preservative	Relevant to microbial control, but requires tolerability and regulatory assessment
Purified water or water for injection	Vehicle	Controls extractables, impurities and manufacturing consistency
Nasal actuator and container	Delivery system	Determines plume geometry, droplet-size distribution and delivered dose

The distinction between an excipient and a delivery component is commercially important. A simple formulation may have limited composition-of-matter protection, while the actuator, pump, container, manufacturing process and dose-delivery profile can create stronger regulatory and commercial barriers.

How can excipients improve naloxone nasal delivery?

Naloxone is a suitable candidate for intranasal rescue therapy because rapid systemic exposure can be obtained without needles or patient training. Excipients can support five development objectives:

1. Chemical stability. pH adjustment and control of formulation impurities can reduce degradation during long-term storage.
2. Physical stability. The formulation should remain homogeneous and free of precipitation or visible particles.
3. Nasal tolerability. Osmolality, pH, preservative level and spray volume affect burning, irritation and user acceptance.
4. Device performance. Viscosity and surface tension influence droplet size, plume shape and dose uniformity.
5. Packaging compatibility. The formulation must be compatible with elastomers, plastics, adhesives and actuator components throughout shelf life.

A commercial developer should avoid unnecessary excipient complexity. Each additional excipient creates new extractables, leachables, toxicology, stability and scale-up considerations. For naloxone, a minimalist aqueous platform is generally more defensible than a heavily engineered formulation unless the product targets a specific technical problem.

What formulation strategies could differentiate a naloxone product?

Preservative-free single-dose nasal sprays

A preservative-free formulation can reduce concerns about local irritation and chronic exposure to benzalkonium chloride. The tradeoff is greater dependence on single-use packaging, microbial controls and container-closure integrity.

This strategy is commercially attractive for OTC products intended for repeated stocking in homes, schools, workplaces and public-access cabinets. It can also support differentiation in populations with frequent administration or sensitive nasal tissue.

Higher-concentration and lower-volume sprays

A higher-strength product can deliver the required dose in a small volume. The commercial benefit is a compact package and potentially lower risk of runoff from the nasal cavity. The development risk is greater local concentration, possible irritation and the need to demonstrate consistent atomization.

Kloxxado uses an 8 mg dose, compared with the 4 mg dose used for Narcan and many generic products. The product targets concerns about potent synthetic opioids and delayed or incomplete response.[4]

Mucoadhesive formulations

Mucoadhesive polymers can increase residence time in the nasal cavity. Candidate technologies may include low levels of cellulose derivatives, polyvinylpyrrolidone or other mucoadhesive polymers. These systems require careful control of viscosity because excessive residence time can impair sprayability and dose reproducibility.

Mucoadhesive claims are commercially meaningful only if supported by pharmacokinetic, device-performance and clinical data. A formulation that produces slower absorption may not improve the clinical profile of an emergency rescue product.

Absorption-enhanced formulations

Permeation enhancers may improve nasal uptake, particularly at lower doses or in formulations with reduced spray volume. Potential categories include surfactants, bile-salt derivatives and other nasal absorption technologies. These compounds can introduce local toxicity, irritation, variability and regulatory complexity.

The commercial opportunity is stronger where an absorption enhancer enables a material reduction in dose or actuator size. Without a measurable pharmacokinetic or usability advantage, the added excipient burden may not justify the development cost.

Pediatric and lower-dose products

Pediatric rescue products could use lower dose strengths or more controlled administration. The market includes households, schools, pediatric emergency services and institutional caregivers. Dose reduction must be balanced against the risk of under-treatment in an emergency.

A pediatric product could be differentiated through dose metering, tamper-evident packaging, simplified instructions and age-specific labeling rather than through a novel excipient alone.

What formulation patents protect naloxone products?

Naloxone patent value is concentrated in delivery systems, formulations, devices and methods of use. Basic naloxone hydrochloride composition claims have limited commercial value because the active ingredient is long established.

Potentially protectable subject matter includes:

• Nasal formulations with specified pH, osmolality or excipient ratios.
• Preservative-free or low-preservative formulations.
• High-concentration naloxone solutions.
• Mucoadhesive or absorption-enhanced formulations.
• Actuator designs that produce a defined plume and droplet-size distribution.
• Container-closure systems that preserve dose accuracy.
• Prefilled syringe or autoinjector configurations.
• Methods for treating opioid overdose with specified doses or repeat-dose protocols.
• Manufacturing processes that reduce degradation or improve device filling.
• Packaging systems designed for long-term storage in uncontrolled environments.

How strong is the patent estate for naloxone?

The estate is generally stronger around device architecture and integrated drug-device performance than around conventional excipients. A patent claiming sodium chloride, hydrochloric acid, benzalkonium chloride and water in a standard aqueous naloxone formulation may face obviousness and written-description challenges if the ranges are broad or predictable.

A stronger claim set would link composition to a measurable result, such as:

• Defined delivered-dose uniformity.
• Specified droplet-size distribution.
• Improved stability under elevated temperature and humidity.
• Reduced nasal irritation.
• Improved pharmacokinetic exposure.
• Compatibility with a defined container or actuator.
• Consistent performance after environmental aging.

Companies should conduct a current USPTO, FDA Orange Book and Patent Center review before relying on any specific patent term. Product-related rights can differ by strength, dosage form, device, listed patent and litigation history.

What is the FDA and Orange Book status of naloxone?

Naloxone nasal sprays are regulated as drug products with important drug-device characteristics. FDA review focuses on formulation quality, dose delivery, human factors, container closure, stability, nasal tolerability and clinical or pharmacokinetic bridging.

The OTC transition changes the commercial model. Prescription products can rely on professional prescribing and institutional procurement. OTC products must communicate use instructions directly to nonclinical caregivers and compete in retail, e-commerce and mass-merchandising channels.

The Orange Book is relevant for FDA-approved prescription products and listed patents. OTC products may have different patent-listing and exclusivity dynamics depending on the application pathway and regulatory status. Naloxone developers should not assume that every formulation or device patent will appear in the Orange Book.

FDA exclusivity for naloxone is limited compared with products containing new active ingredients. A sponsor’s practical exclusivity is more likely to arise from:

• Product-specific patents.
• Device patents.
• Manufacturing know-how.
• OTC brand recognition.
• Institutional contracts.
• Regulatory timing.
• Manufacturing capacity.
• Switching costs in public-health programs.

When does naloxone lose exclusivity?

Naloxone lost active-ingredient exclusivity decades ago. The commercial question is whether a particular branded nasal spray, injectable presentation or device retains product-specific protection.

The main competitive events are:

Event	Commercial impact
Expiration of product or device patents	Enables additional approved competition
FDA approval of generic nasal spray	Reduces pricing power in retail and institutional channels
OTC approval	Expands consumer access but increases direct price competition
Public procurement awards	Can shift volume rapidly among suppliers
Manufacturing disruption	Creates temporary supply opportunities
New high-dose or device format	Supports segmentation rather than durable monopoly pricing

Unlike biologics such as monoclonal antibodies, naloxone does not face biosimilar risk. It is a small-molecule generic-drug market. The relevant challenge is ANDA competition, not the 351(k) biosimilar pathway.

Which companies are challenging or competing with naloxone brands?

The competitive field includes generic manufacturers, branded nasal-spray sponsors, nonprofit suppliers and injectable manufacturers.

Retail and OTC competition

Narcan established the dominant consumer-facing brand, but OTC competition from RiVive and Teva creates pricing pressure. The principal commercial variables are shelf placement, retailer coverage, package size, insurance status, public-health distribution and consumer recognition.

Institutional and government competition

State agencies, municipalities, schools, universities, first responders and harm-reduction organizations purchase naloxone through grants, public contracts and bulk procurement. These buyers place a higher value on unit cost, delivery reliability, expiration dating and training materials than on brand prestige.

Hospital and emergency-service competition

Injectable naloxone remains important in hospitals, ambulances and emergency departments. Suppliers compete on vial and syringe formats, concentration, availability, contract pricing and shortage resilience.

What commercial opportunities exist for naloxone excipients?

The most credible opportunities are enabling technologies rather than stand-alone excipients.

Excipient suppliers

Excipient companies can target:

• Low-irritation preservatives.
• Preservative-free sterile systems.
• Nasal absorption enhancers with established safety data.
• Low-viscosity mucoadhesive polymers.
• Packaging-compatible surfactants.
• Stabilizers that reduce oxidation or hydrolysis.
• Excipient systems qualified for high-temperature distribution.

A supplier with an existing nasal-delivery safety package has a stronger position than one offering an untested excipient with only theoretical absorption benefits.

Contract development and manufacturing

CDMOs can offer value through:

• Nasal spray filling.
• Device assembly.
• Automated dose testing.
• Stability programs.
• Extractables and leachables packages.
• Combination-product quality systems.
• Rapid scale-up for public-sector contracts.

The ability to manufacture at high volume and low cost is a major competitive advantage because naloxone buyers frequently compare landed unit price.

Private-label and co-branded products

Retailers, pharmacies, employers, schools and health systems may seek private-label naloxone. A platform based on an approved nasal formulation and established actuator can shorten development timelines, subject to regulatory and intellectual-property constraints.

The opportunity is strongest where a sponsor can combine:

• Low manufacturing cost.
• OTC labeling.
• Multiple package configurations.
• Reliable supply.
• Simple training materials.
• Large-volume procurement support.

Global and geographic expansion

Opportunities exist in jurisdictions where opioid mortality is rising or where governments are expanding take-home naloxone programs. Regulatory requirements differ across the United States, Canada, Europe, Australia and emerging markets. Local opportunities may favor injectable products where nasal products have not secured approval or reimbursement.

Geographic protection may arise from national patents, regulatory approvals, trademarks, procurement contracts and local manufacturing arrangements. Patent coverage alone is unlikely to determine market access in low-price public-health markets.

What manufacturing and IP barriers affect naloxone?

The main manufacturing barriers are sterile processing, accurate low-volume filling, device assembly and quality control. Nasal products require consistent delivered dose and spray performance across the full shelf life. A formulation that performs well in laboratory testing may fail after actuator aging, temperature cycling or transport vibration.

Critical technical controls include:

• Assay and impurity specifications.
• pH and osmolality.
• Delivered-volume accuracy.
• Spray content uniformity.
• Droplet-size distribution.
• Plume geometry.
• Microbial limits or sterility controls.
• Container-closure integrity.
• Extractables and leachables.
• Stability under ICH conditions and excursion temperatures.

IP barriers are more likely to involve integrated drug-device claims, process parameters and proprietary testing data than the use of a conventional excipient. Freedom-to-operate analysis should cover formulation, actuator, pump, container, filling process, packaging and labeling claims.

What generic launch scenarios exist for naloxone?

Low-cost OTC nasal spray

This is the most direct competitive scenario. A generic or authorized generic can compete on price, retailer access and public-sector volume. The principal risk to branded products is rapid substitution when buyers perceive equivalent dose delivery and quality.

Premium high-dose nasal spray

A higher-dose product may preserve pricing through clinical positioning and perceived relevance to potent synthetic opioids. The risk is that buyers may use lower-priced 4 mg products with repeat dosing instead.

Institutional prefilled syringe

A syringe format can compete in emergency services and hospitals where needle-based administration is already established. Its advantage is controlled dosing and familiar workflow. Its limitations are needle use, training and lower suitability for public access.

Device-led rescue product

An autoinjector or voice-guided product can support premium pricing if it materially improves use by untrained caregivers. Device cost, reimbursement and supply complexity remain substantial barriers.

How does naloxone compare with other emergency rescue medicines?

Naloxone has a broader public-access market than many emergency medicines because it is distributed through pharmacies, harm-reduction programs, schools and community organizations. It also has lower active-ingredient complexity than epinephrine autoinjectors or biologic rescue products.

Factor	Naloxone nasal spray	Epinephrine autoinjector	Injectable naloxone
Active ingredient complexity	Low	Low	Low
Device dependence	High	Very high	Moderate
OTC potential	Established	Limited in the U.S.	Low
Training burden	Low	Moderate	High
Public-sector demand	High	Moderate	High
Excipient differentiation	Moderate	Moderate	Low
Device and packaging value	High	Very high	Moderate
Biosimilar risk	None	None	None

What is the revenue exposure for naloxone manufacturers?

Revenue exposure depends on channel mix rather than only prescription volume. The principal risks are:

• OTC price erosion.
• Public-sector tender losses.
• Retailer private-label substitution.
• Reduced reimbursement after OTC conversion.
• Product recalls or device failures.
• Shortages of pumps, actuators or sterile components.
• Dependence on a single contract manufacturer.
• Procurement concentration among government buyers.

The strongest revenue defense is a diversified portfolio covering OTC retail, institutional contracts, injectable supply and international markets. A single branded nasal spray remains vulnerable to generic entry and tender-based pricing.

Key Takeaways

• Naloxone excipient innovation has value when it improves stability, tolerability, spray performance or shelf life.
• Conventional aqueous excipients provide limited standalone patent protection.
• The strongest IP opportunities involve integrated formulation-device performance, packaging and manufacturing processes.
• OTC approval has expanded the market while increasing direct price competition.
• Naloxone has no biosimilar risk; generic ANDA competition is the relevant pathway.
• Public-sector procurement, school programs, harm-reduction distribution and retail access are the main commercial channels.
• Preservative-free systems, high-dose sprays, pediatric formats, robust packaging and low-cost manufacturing are the most credible product-development opportunities.
• Device reliability, scale manufacturing and regulatory execution are at least as important as excipient selection.

FAQs About Naloxone Excipient and Commercial Strategy

Can a new preservative create a defensible naloxone patent?

Yes, but the claim is stronger when the preservative produces demonstrated improvements in nasal tolerability, stability, microbial control or device compatibility. A routine substitution without unexpected results may face obviousness challenges.

Is benzalkonium chloride essential in naloxone nasal spray?

No. It is used in some aqueous nasal products for antimicrobial preservation, but a sponsor may pursue a preservative-free single-dose system or another preservation approach if supported by manufacturing and stability data.

Is a high-dose naloxone spray commercially superior?

Not necessarily. High-dose products may appeal to buyers concerned about potent opioids, but lower-dose products can be less expensive and may be administered repeatedly. The outcome depends on clinical positioning, procurement policy and price.

Can an excipient supplier commercialize a naloxone nasal platform without owning a drug product?

Yes. The supplier can license an excipient system, provide formulation development, support regulatory filings or partner with a CDMO. The platform must have nasal safety, manufacturing and compatibility data.

Does naloxone require a biosimilar strategy?

No. Naloxone is a small-molecule drug. Competitive development generally proceeds through generic-drug pathways, approved drug applications, OTC applications or a new drug application for a differentiated formulation or device.

References

1. U.S. Food and Drug Administration. (2023). FDA approves first over-the-counter naloxone nasal spray. https://www.fda.gov
2. U.S. Food and Drug Administration. (2023). FDA approves prescription naloxone nasal spray for nonprescription use. https://www.fda.gov
3. U.S. Food and Drug Administration. (2024). FDA approves first generic naloxone nasal spray for nonprescription use. https://www.fda.gov
4. Hikma Pharmaceuticals. (2024). Kloxxado naloxone hydrochloride nasal spray prescribing information. https://www.accessdata.fda.gov
5. Emergent BioSolutions. (2024). Narcan naloxone hydrochloride nasal spray prescribing information. https://www.accessdata.fda.gov
6. Harm Reduction Therapeutics. (2024). RiVive naloxone hydrochloride nasal spray prescribing information. https://www.accessdata.fda.gov
7. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov
8. United States Pharmacopeia. (2024). General chapters for nasal drug products, delivered-dose uniformity and pharmaceutical packaging. https://www.usp.org
9. U.S. Food and Drug Administration. (2020). Nasal spray and inhalation solution, suspension, and spray drug products: Chemistry, manufacturing, and controls documentation. https://www.fda.gov